The Organoid group at the Hubrecht Institute have identified a new link between FBXW7 mutations and EGFR signaling activity. The FBXW7 gene is commonly mutated in colorectal cancer and such mutations ...

Survey of actionable driver mutations KRAS and EGFR in non–small cell lung cancer to evaluate coexisting splicing gene and pathway mutations: A CBioportal database analysis. This is an ASCO Meeting ...

Drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, occurring via secondary mutations or bypass pathways, is frequent among non-small-cell lung cancer patients.

WU-KONG28 was an open-label, randomized, confirmatory phase 3 study across 16 countries, using blinded independent central ...

Hutchmed begins global clinical trial of PI3K/PIKK-EGFR ATTC candidate HMPL-A580 in patients with solid tumours: Hong Kong, Shanghai Friday, March 6, 2026, 10:00 Hrs [IST] Hutchme ...

For the purpose of clarity, the signaling pathways can be discussed in isolation. However, in reality there is considerable cross-talk between pathways, with parallel or upstream input from other ...

EGFR-positive lung cancer is more common in non-smokers (particularly those with adenocarcinoma) and younger adults, as it often develops from a single genetic mutation rather than widespread DNA ...